FIPA 2 Exam 3 Practice Exam

Which statement best defines bioequivalence in generic drug approval?

The generic's rate and extent of absorption are not significantly different from the reference product The generic must be manufactured by the same facility The generic must be identical chemically The generic must be marketed on the same day as the reference

Correct Answer:

The generic must be manufactured by the same facility

Explanation:

Bioequivalence means the generic product delivers the same amount of active drug into the bloodstream over the same time period as the reference product, so its rate and extent of absorption are not significantly different. This ensures similar efficacy and safety, since the body sees essentially the same exposure to the medicine. The defining idea captured here is that the generic’s rate and extent of absorption are not significantly different from the reference product. Manufacturing in the same facility, exact chemical identity in every detail, or launching on the same day as the reference do not determine bioequivalence. Excipients and formulations can differ, and approvals focus on pharmacokinetic similarity rather than site of manufacture or timing of market entry.

Access more questions from this quiz

Continue to FIPA 2 Exam 3 Practice Exam for more practice questions and the full quiz experience.

Access More Questions